BioBridges has been engaged by an established, San Francisco-based pharmaceutical company to provide bio-statistical expertise to two new early clinical programs by supporting fractional factorial design, reviewing study designs and creating statistical protocols.
BioBridges has been engaged by an emerging pharmaceutical company to create a clinical protocol and support the end of a Phase 2 dermatology study and initiation of Phase 3.
BioBridges has been engaged by a clinical-stage biopharmaceutical company to provide supply chain management services, including; IRT management of inventory, management of global stock, label generation, and day-to-day issue escalation and resolution.
BioBridges has been engaged by an established, Massachusetts-based pharmaceutical company to manage a Phase II respiratory study in accordance with existing SOPs, while maintaining agreed upon timelines and budget and increasing cross-functional communication.
BioBridges has been engaged by an emerging, New York-based biotechnology company focused on neurological diseases to provide regulatory leadership, strategy and execution for two active programs.
BioBridges has been engaged by an established, California-based, immuno-oncology company to implement, manage, and monitor clinical trial activities, ensuring on-time, within budget and in compliance completion.
BioBridges has been engaged by an emerging, Utah-based, biopharmaceutical company to oversee outsourced work and strategize and execute an appropriate analysis of all incoming vendor data.
BioBridges has been engaged by an emerging biotechnology company to oversee a series of US- and EU-based oncology studies as they move out of Ph1b and into dose expansion.
BioBridges has been engaged by an emerging clinical-stage biotechnology company to develop and enforce quality assurance processes and oversee general quality systems, document reviews, and audits.
BioBridges has been engaged by a California-based, oncology-focused biopharmaceutical company to ensure the accuracy and consistency of all clinical databases while maintaining the companies policies and procedures for gathering, analyzing and reporting clinical data.